Efficacy of Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathy (CHEMOSTIM)
Efficacy of Posterior Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathic Pain: A Multicenter Randomized Crossover Trial
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and debilitating side effect of many cancer treatments. It affects 28 to 48% of patients receiving chemotherapy. Symptoms include tingling, numbness, burning sensations, and pain mainly in the hands and feet. While CIPN often improves after chemotherapy ends, in some patients the pain persists and becomes chronic, severely impairing quality of life, sleep, and daily functioning.
Currently, no treatment has been shown to prevent CIPN. For patients with chronic pain, duloxetine is the only recommended drug, but its efficacy is limited. When standard medications fail, patients have very few options.
Spinal cord stimulation (SCS) is a well-established neurosurgical technique used to treat various forms of chronic neuropathic pain, including pain after surgery, trauma, or diabetes. In this procedure, thin electrodes are placed in the epidural space near the spinal cord and connected to a small implantable pulse generator. The electrical impulses delivered by the device modulate pain signals in the nervous system.
Preliminary case reports suggest that SCS may be effective in patients with CIPN, but no randomized controlled trial has yet established its value in this specific indication. The CHEMOSTIM study aims to fill this gap.
CHEMOSTIM is a multicenter, prospective, randomized crossover trial. All enrolled patients will undergo SCS implantation. Participants will then be randomized to receive either active stimulation first followed by sham stimulation, or sham stimulation first followed by active stimulation. In the sham phase, the device is implanted but switched off following a simulated programming session, so patients cannot tell which phase they are in.
The primary outcome is the proportion of patients achieving more than 50% pain reduction on a Visual Analog Scale (VAS) during the active stimulation phase compared to the sham stimulation phase, assessed at 4 months.
Secondary outcomes include changes in quality of life, anxiety and depression, sleep quality, medication use, individualized goal attainment, neurological examination, and nerve conduction studies. The study will also evaluate post-stimulation effects and complications.
Eligible patients are adults with chronic CIPN evolving for at least one year, with pain greater than 5/10 in the lower limbs, who have failed at least two lines of pharmacological treatment (antidepressants, anticonvulsants, topical agents, etc.) and whose indication for SCS has been validated by a multidisciplinary team following SFETD/SFNM guidelines.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Anne MD PHD BALOSSIER
- 电话号码:+33491384277
- 邮箱:anne.balossier@ap-hm.fr
学习地点
-
-
-
Marseille、法国
- Hôpital de la Timone
-
接触:
- François CREMIEUX
- 电话号码:+33491382001
- 邮箱:francois.cremieux@ap-hm.fr
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Adult patient with chemotherapy-induced painful neuropathy (platinum salts, vincristine, taxanes, alkaloids, epothilone, thalidomide, etc.) evolving for at least 1 year
- Indication for spinal cord stimulation validated by a multidisciplinary team meeting according to SFETD/SFNM guidelines
- Resistance to pharmacological or topical treatment (failure of at least two therapeutic lines or intolerable side effects: anticonvulsants, antidepressants, capsaicin, etc.)
- Pain score > 5/10 on numerical scale in the lower limbs
- Patient able to understand and give informed consent to the protocol
- Patient affiliated to the French Social Security system
- Patient able to complete follow-up questionnaires
Exclusion Criteria:
- 1. Contraindication to spinal cord stimulation:
- Extensive laminectomy
- Coagulopathy
- Intercurrent infections
Psychiatric disorders
2. Body Mass Index (BMI) > 40
3. Life expectancy < 1 year
4. Ongoing pregnancy
5. Patient under guardianship or curatorship
6. Patient already implanted with a spinal cord stimulation device
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Active stimulation first - Sham stimulation second
Participants receive active spinal cord stimulation (FAST mode, sub-perception) for 4 months, followed by sham stimulation (device switched off) for 3 months.
|
Sub-perception spinal cord stimulation delivered in FAST mode at 10% below perception threshold.
The remote control is sealed and given to the patient with instructions not to use it.
|
|
假比较器:Sham stimulation first → Active stimulation second
Participants receive sham stimulation (device switched off) for 3 months, followed by active spinal cord stimulation (FAST mode, sub-perception) for 4 months.
|
The implanted device is switched off following a simulated programming session identical to the active phase (perception threshold verified, stimulation reduced to 80% of threshold, then switched off).
Patients are unable to distinguish sham from active stimulation.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Proportion of patients with ≥50% pain reduction on Visual Analog Scale (VAS)
大体时间:4 months (end of first stimulation sequence)
|
4 months (end of first stimulation sequence)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Global Impression of Change
大体时间:4 months and 7 months
|
4 months and 7 months
|
|
Anxiety and Depression (HADS)
大体时间:4 months and 7 months
|
4 months and 7 months
|
|
Sleep Quality (Pittsburgh Sleep Quality Index)
大体时间:4 months and 7 months
|
4 months and 7 months
|
|
Medication consumption
大体时间:4 months and 7 months
|
4 months and 7 months
|
|
Goal Attainment Scale (GAS)
大体时间:4 months and 7 months
|
4 months and 7 months
|
|
Device and stimulation-related complications
大体时间:7 months
|
7 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.